Celularity Inc. Other Nonoperating Expense
Celularity Inc. (CELU) reported Other Nonoperating Expense of $6.75 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingExpense · last filed 2026-04-30
- Celularity Inc. other nonoperating expense for the quarter ending 2025-12-31 was $897.00K, a 50.50% decline year-over-year.
- Celularity Inc. other nonoperating expense for the quarter ending 2025-09-30 was $1.48M, a 15.70% decline year-over-year.
- Celularity Inc. other nonoperating expense for the quarter ending 2025-06-30 was $1.94M, a 25.19% increase year-over-year.
- Celularity Inc. other nonoperating expense for the quarter ending 2025-03-31 was $2.44M, a 112.28% increase year-over-year.
- Celularity Inc. other nonoperating expense for fiscal 2025 was $6.75M, a 7.82% increase from fiscal 2024.
- Celularity Inc. other nonoperating expense for fiscal 2024 was $6.26M, a 107.76% increase from fiscal 2023.
- Celularity Inc. other nonoperating expense for fiscal 2023 was $3.02M.
- Celularity Inc. other nonoperating expense for fiscal 2021 was $3.17M, a 34.71% increase from fiscal 2020.
| Period end | Other Nonoperating Expense 3 month | Other Nonoperating Expense 6 month | Other Nonoperating Expense 9 month | Other Nonoperating Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $897.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $2.37M derived: sum of 2 quarters · filed 2026-04-30 | $4.32M derived: sum of 3 quarters · filed 2026-04-30 | $6.75M 10-K · filed 2026-04-30 |
| 2025-09-30 | $1.48M 10-Q · filed 2025-11-14 | $3.42M derived: sum of 2 quarters · filed 2025-11-14 | $5.86M 10-Q · filed 2025-11-14 | $7.67M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-06-30 | $1.94M 10-Q · filed 2025-08-29 | $4.38M 10-Q · filed 2025-08-29 | $6.19M derived: sum of 3 quarters · filed 2026-04-30 | $7.94M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-03-31 | $2.44M 10-Q · filed 2025-08-29 | $4.25M derived: sum of 2 quarters · filed 2026-04-30 | $6.00M derived: sum of 3 quarters · filed 2026-04-30 | $7.55M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $3.56M derived: sum of 2 quarters · filed 2026-04-30 | $5.12M derived: sum of 3 quarters · filed 2026-04-30 | $6.26M 10-K · filed 2026-04-30 |
| 2024-09-30 | $1.75M 10-Q · filed 2025-11-14 | $3.30M derived: sum of 2 quarters · filed 2025-11-14 | $4.45M 10-Q · filed 2025-11-14 | $5.12M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.55M 10-Q · filed 2025-08-29 | $2.70M 10-Q · filed 2025-08-29 | $3.36M derived: sum of 3 quarters · filed 2025-08-29 | $4.33M derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-03-31 | $1.15M 10-Q · filed 2025-08-29 | $1.81M derived: sum of 2 quarters · filed 2025-08-29 | $2.78M derived: sum of 3 quarters · filed 2025-08-29 | $3.89M derived: sum of 4 quarters · filed 2025-08-29 |
| 2023-12-31 | $663.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | $1.63M derived: sum of 2 quarters · filed 2025-05-08 | $2.74M derived: sum of 3 quarters · filed 2025-05-08 | $3.02M 10-K · filed 2025-05-08 |
| 2023-09-30 | $971.00K 10-Q · filed 2024-12-06 | $2.08M derived: sum of 2 quarters · filed 2024-12-06 | $2.35M 10-Q · filed 2024-12-06 | |
| 2023-06-30 | $1.10M 10-Q · filed 2024-11-07 | $1.38M 10-Q · filed 2024-11-07 | ||
| 2023-03-31 | $277.00K 10-Q · filed 2024-10-16 | |||
| 2022-09-30 | $0.00 10-Q · filed 2024-01-03 | $0.00 derived: sum of 2 quarters · filed 2024-01-03 | $0.00 10-Q · filed 2024-01-03 | $759.00K derived: sum of 4 quarters · filed 2024-01-03 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | $759.00K derived: sum of 3 quarters · filed 2023-08-14 | $1.60M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-22 | $759.00K derived: sum of 2 quarters · filed 2023-05-22 | $1.60M derived: sum of 3 quarters · filed 2023-05-22 | $2.42M derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $759.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.60M derived: sum of 2 quarters · filed 2023-03-31 | $2.42M derived: sum of 3 quarters · filed 2023-03-31 | $3.17M 10-K · filed 2023-03-31 |
| 2021-09-30 | $843.00K 10-Q · filed 2022-11-10 | $1.66M derived: sum of 2 quarters · filed 2022-11-10 | $2.41M 10-Q · filed 2022-11-10 | $3.14M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $817.00K 10-Q · filed 2022-08-09 | $1.57M 10-Q · filed 2022-08-09 | $2.29M derived: sum of 3 quarters · filed 2022-08-09 | $3.00M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $752.00K 10-Q · filed 2022-05-16 | $1.48M derived: sum of 2 quarters · filed 2022-05-16 | $2.18M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $724.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.43M derived: sum of 2 quarters · filed 2022-03-31 | $2.35M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $706.00K 10-Q · filed 2021-11-12 | $1.63M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |